Fenretinide in Young Women at Genetic or Familial Risk of Breast Cancer: A Placebo-Controlled Biomarker Trial.

Valentina Aristarco Davide Serrano Patrick Maisonneuve Aliana Guerrieri-Gonzaga Matteo Lazzeroni Irene Feroce Debora Macis Elena Cavadini Elena Albertazzi Costantino Jemos Emanuela Omodeo Salè Laura Cortesi Samuele Massarut Marcella Gulisano Maria Grazia Daidone Harriet Johansson Bernardo Bonanni

Published in: Cancer prevention research (Philadelphia, Pa.) (2024)

Fenretinide exhibits beneficial effects on the metabolic profile, supporting its clinical use in breast cancer prevention especially in premenopausal women with a positive family history and pathogenic variants in BRCA1/2 genes. This finding requires further investigations in larger trials to confirm its role in breast cancer prevention.

Keyphrases

breast cancer risk
genome wide
study protocol
copy number
phase iii
placebo controlled
phase ii
randomized controlled trial
postmenopausal women
early onset
double blind
gene expression
transcription factor
open label
genome wide identification
phase ii study